----

|   |
|--------|

| x      | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |
|--------|------------------------------------------------------------------------------------------|
|   | For the quarterly period ended June 30, 2013                                             |
|   | Or                                                                                       |
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|   | For the transition period from ___________ to ___________                                |

|   |
|--------|

| Delaware                                                       | 13-3379479                              |
|----------------------------------------------------------------|-----------------------------------------|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |

|   |
|--------|

| Large accelerated filer  ¨                                                          | Accelerated filer   x              |
|-----------------------------------------------------------------------------------------------|-----------------------------------------|
| Non-accelerated filer    ¨  (Do not check if a smaller reporting company) | Smaller reporting company   ¨ |

----

----

|     |                                                                                                    | Page No. |
|----------|---------------------------------------------------------------------------------------------------------|----------|
| Part I   | FINANCIAL INFORMATION                                                                                   |     |
| Item 1.  | Financial Statements                                                                                    |     |
|     | Consolidated Balance Sheets at June 30, 2013 and December 31, 2012                                      | 3        |
|     | Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2013 and 2012         | 4        |
|     | Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2013 and 2012 | 5        |
|     | Consolidated Statements of Stockholders' Equity for the Six Months Ended June 30, 2013 and 2012         | 6        |
|     | Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2013 and 2012                   | 7        |
|     | Notes to Consolidated Financial Statements                                                              | 8        |
| Item 2.  | Management's Discussion and Analysis of Financial Condition and Results of Operations                   | 16       |
| Item 3.  | Quantitative and Qualitative Disclosures about Market Risk                                              | 25       |
| Item 4.  | Controls and Procedures                                                                                 | 26       |
|     |                                                                                                    |     |
| PART II  | OTHER INFORMATION                                                                                       |     |
| Item 1.  | Legal Proceedings                                                                                       | 26       |
| Item 1A. | Risk Factors                                                                                            | 26       |
| Item 6.  | Exhibits                                                                                                | 41       |
|     | Signatures                                                                                              | 42       |

----

|                                                                                                                                               |   | June 30,2013 |     |   | December 31,2012 |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|----------|--------|------------------|--------|
|                                                                                                                                               |   | (Unaudited)  |     |   |                  |   |
| ASSETS                                                                                                                                             |   |              |     |   |                  |   |
| Current assets:                                                                                                                                    |   |              |     |   |                  |   |
| Cash and cash equivalents                                                                                                                          |   | $            | 79,221   |   |             | $      | 58,838 |   |
| Accounts receivable                                                                                                                                |   |         | 1,250    |   |             |   | 6,937 |   |
| Other current assets                                                                                                                               |   |         | 1,453    |   |             |   | 1,692 |   |
| Total current assets                                                                                                                               |   |         | 81,924   |   |             |   | 67,467 |   |
| Auction rate  securities                                                                                                                      |   |         | 2,208    |   |             |   | 3,240 |   |
| Fixed assets, at cost, net of accumulated depreciation and amortization                                                                            |   |         | 2,676    |   |             |   | 3,399 |   |
| Deferred tax asset – long term                                                                                                               |   |         | -        |   |             |   | 2,052 |   |
| Intangible assets                                                                                                                                  |   |         | 32,300   |   |             |   | - |   |
| Goodwill                                                                                                                                           |   |         | 7,702    |   |             |   | - |   |
| Other assets                                                                                                                                       |   |         | 150      |   |             |   | 150 |   |
|      Total assets                                                                                                         |   | $            | 126,960  |   |             | $      | 76,308 |   |
|                                                                                                                                               |   |         |     |   |             |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                                               |   |         |     |   |             |   |   |   |
| Current  liabilities:                                                                                                                         |   |         |     |   |             |   |   |   |
| Accounts payable and accrued expenses                                                                                                              |   | $            | 5,961    |   |             | $      | 5,640 |   |
| Deferred tax liability – current                                                                                                             |   |         | -        |   |             |   | 2,069 |   |
| Deferred  revenue – current                                                                                                             |   |         | 106      |   |             |   | 838 |   |
| Other current liabilities                                                                                                                          |   |         | 115      |   |             |   | 115 |   |
| Total current liabilities                                                                                                                          |   |         | 6,182    |   |             |   | 8,662 |   |
| Acquisition-related contingent consideration liability                                                                                             |   |         | 15,900   |   |             |   | - |   |
| Deferred tax liability – long term                                                                                                           |   |         | 12,683   |   |             |   | - |   |
| Other  liabilities                                                                                                                            |   |         | 915      |   |             |   | 1,078 |   |
| Total liabilities                                                                                                                                  |   |         | 35,680   |   |             |   | 9,740 |   |
| Commitments and contingencies (Note 10)                                                                                                            |   |         |     |   |             |   |   |   |
| Stockholders'  equity:                                                                                                                        |   |         |     |   |             |   |   |   |
| Preferred stock, $.001 par value; 20,000,000 shares authorized; issued and outstanding - none                                                      |   |         | -        |   |             |   | - |   |
| Common stock, $.0013 par value; shares authorized - 160,000,000 in 2013 and 80,000,000 in 2012; issued - 59,737,697 in 2013 and 46,765,472 in 2012 |   |         | 78       |   |             |   | 61 |   |
| Additional paid-in capital                                                                                                                         |   |         | 541,761  |   |             |   | 493,613 |   |
| Accumulated deficit                                                                                                                                |   |         | (447,626 | )      |             |   | (424,105 | ) |
| Accumulated other comprehensive loss                                                                                                               |   |         | (192     | )      |             |   | (260 | ) |
| Treasury stock, at cost (200,000 shares in 2013 and 2012)                                                                                          |   |         | (2,741   | )      |             |   | (2,741 | ) |
|   Total stockholders' equity                                                                                                                  |   |         | 91,280   |   |             |   | 66,568 |   |
|   Total liabilities and stockholders' equity                                                                                                  |   | $            | 126,960  |   |             | $      | 76,308 |   |

----

|                                                                                         |   | For the Three Months Ended |    |   | For the Six Months Ended |   |
|----------------------------------------------------------------------------------------------|--------|----------------------------|---------|--------|--------------------------|--------|
|                                                                                         |   | June 30,                   |    |   | June 30,                 |   |
|                                                                                         |   | 2013                       |    |   | 2012                     |   |   | 2013 |   |   | 2012 |   |
| Revenues:                                                                                    |   |                            |    |   |                          |   |   |  |   |   |  |   |
| Royalty income                                                                               |   | $                          | 1,176   |   |                     | $      | 1,619 |   |   | $ | 2,333 |   |   | $ | 3,453 |   |
| Collaboration revenue                                                                        |   |                       | 514     |   |                     |   | 94 |   |   |   | 1,367 |   |   |   | 385 |   |
| Research grants                                                                              |   |                       | 77      |   |                     |   | 88 |   |   |   | 275 |   |   |   | 174 |   |
| Other revenues                                                                               |   |                       | 34      |   |                     |   | 19 |   |   |   | 52 |   |   |   | 34 |   |
| Total revenues                                                                               |   |                       | 1,801   |   |                     |   | 1,820 |   |   |   | 4,027 |   |   |   | 4,046 |   |
|                                                                                         |   |                       |    |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Expenses:                                                                                    |   |                       |    |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Research and development                                                                     |   |                       | 10,068  |   |                     |   | 7,957 |   |   |   | 18,789 |   |   |   | 18,866 |   |
| License fees – research and development                                                |   |                       | 153     |   |                     |   | 110 |   |   |   | 223 |   |   |   | 150 |   |
| Royalty expense                                                                              |   |                       | 119     |   |                     |   | 162 |   |   |   | 235 |   |   |   | 347 |   |
| General and administrative                                                                   |   |                       | 3,416   |   |                     |   | 4,025 |   |   |   | 7,730 |   |   |   | 7,746 |   |
| Depreciation and amortization                                                                |   |                       | 318     |   |                     |   | 300 |   |   |   | 595 |   |   |   | 772 |   |
| Total expenses                                                                               |   |                       | 14,074  |   |                     |   | 12,554 |   |   |   | 27,572 |   |   |   | 27,881 |   |
|                                                                                         |   |                       |    |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Operating loss                                                                               |   |                       | (12,273 | )      |                     |   | (10,734 | ) |   |   | (23,545 | ) |   |   | (23,835 | ) |
|                                                                                         |   |                       |    |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Other income:                                                                                |   |                       |    |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Interest income                                                                              |   |                       | 10      |   |                     |   | 14 |   |   |   | 24 |   |   |   | 29 |   |
| Total other income                                                                           |   |                       | 10      |   |                     |   | 14 |   |   |   | 24 |   |   |   | 29 |   |
|                                                                                         |   |                       |    |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                     |   | $                          | (12,263 | )      |                     | $      | (10,720 | ) |   | $ | (23,521 | ) |   | $ | (23,806 | ) |
|                                                                                         |   |                       |    |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Net loss per share – basic and diluted                                                 |   | $                          | (0.24   | )      |                     | $      | (0.32 | ) |   | $ | (0.46 | ) |   | $ | (0.70 | ) |
|         Weighted-average shares – basic and diluted |   |                       | 51,481  |   |                     |   | 33,798 |   |   |   | 50,802 |   |   |   | 33,779 |   |

----

|                                                     |   | For the Three Months Ended |    |   | For the Six Months Ended |   |
|----------------------------------------------------------|--------|----------------------------|---------|--------|--------------------------|--------|
|                                                     |   | June 30,                   |    |   | June 30,                 |   |
|                                                     |   | 2013                       |    |   | 2012                     |   |   | 2013 |   |   | 2012 |   |
|                                                     |   |                            |    |   |                          |   |   |  |   |   |  |   |
| Net loss                                                 |   | $                          | (12,263 | )      |                     | $      | (10,720 | ) |   | $ | (23,521 | ) |   | $ | (23,806 | ) |
| Other comprehensive income:                              |   |                       |    |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Net change in unrealized loss on auction rate securities |   |                       | 60      |   |                     |   | - |   |   |   | 68 |   |   |   | 8 |   |
| Total other comprehensive income                         |   |                       | 60      |   |                     |   | - |   |   |   | 68 |   |   |   | 8 |   |
| Comprehensive loss                                       |   | $                          | (12,203 | )      |                     | $      | (10,720 | ) |   | $ | (23,453 | ) |   | $ | (23,798 | ) |

----

|                                                                                                                         |   | Common Stock |   |   |        |   |   |                           |   |   | Accumulated Other  |   |   | Treasury Stock             |     |   |        |   |
|------------------------------------------------------------------------------------------------------------------------------|--------|--------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------------------|--------|--------|----------------------------|----------|--------|--------|--------|
|                                                                                                                         |   | Shares       |   |   | Amount |   |   | AdditionalPaid-In Capital |   |   | AccumulatedDeficit |   |   | ComprehensiveIncome (Loss) |     |   | Shares |   |   | Amount |   |   | Total |   |
| Balance at December 31,  2012                                                                                           |   |         | 46,765 |   |   | $      | 61     |                      |   | $      | 493,613            |   |   | $                          | (424,105 | )      |   | $      | (260 | ) |   |   | (200 | ) |   | $ | (2,741 | ) |   | $ | 66,568 |   |
| Net loss                                                                                                                     |   |         | -      |   |   |   | -      |                      |   |   | -                  |   |   |                       | (23,521  | )      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (23,521 | ) |
| Other comprehensive income                                                                                                   |   |         | -      |   |   |   | -      |                      |   |   | -                  |   |   |                       | -        |   |   |   | 68 |   |   |   | - |   |   |   | - |   |   |   | 68 |   |
|    Compensation expenses for share-based payment arrangements                                                 |   |         | -      |   |   |   | -      |                      |   |   | 2,099              |   |   |                       | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 2,099 |   |
| Acquisition of subsidiary, net of issuance costs                                                                             |   |         | 4,472  |   |   |   | 6      |                      |   |   | 11,214             |   |   |                       | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 11,220 |   |
| Sale of common stock in public offering, net of underwriting discounts and commissions ($2,244) and offering expenses ($314) |   |         | 8,500  |   |   |   | 11     |                      |   |   | 34,832             |   |   |                       | -        |   |   |   | - |   |   |   |   |   |   |   | - |   |   |   | 34,843 |   |
| Exercise of stock options                                                                                                    |   |         | 1      |   |   |   | -      |                      |   |   | 3                  |   |   |                       | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 3 |   |
| Balance at June 30, 2013                                                                                                     |   |         | 59,738 |   |   | $      | 78     |                      |   | $      | 541,761            |   |   | $                          | (447,626 | )      |   | $      | (192 | ) |   |   | (200 | ) |   | $ | (2,741 | ) |   | $ | 91,280 |   |

|                                                       |   | Common Stock |   |   |        |   |   |                           |   |   | Accumulated Other   |   |   | Treasury Stock             |     |   |        |   |
|------------------------------------------------------------|--------|--------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|---------------------|--------|--------|----------------------------|----------|--------|--------|--------|
|                                                       |   | Shares       |   |   | Amount |   |   | AdditionalPaid-In Capital |   |   | Accumulated Deficit |   |   | ComprehensiveIncome (Loss) |     |   | Shares |   |   | Amount |   |   | Total |   |
| Balance at December 31,  2011                         |   |         | 34,046 |   |   | $      | 44     |                      |   | $      | 463,440             |   |   | $                          | (388,674 | )      |   | $      | (268 | ) |   |   | (200 | ) |   | $ | (2,741 | ) |   | $ | 71,801 |   |
| Net loss                                                   |   |         | -      |   |   |   | -      |                      |   |   | -                   |   |   |                       | (23,806  | )      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (23,806 | ) |
| Other comprehensive income                                 |   |         | -      |   |   |   | -      |                      |   |   | -                   |   |   |                       | -        |   |   |   | 8 |   |   |   | - |   |   |   | - |   |   |   | 8 |   |
| Compensation expenses for share-based payment arrangements |   |         | -      |   |   |   | -      |                      |   |   | 4,796               |   |   |                       | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 4,796 |   |
| Forfeitures of restricted stock                            |   |         | (2     | )      |   |   | -      |                      |   |   | -                   |   |   |                       | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Exercise of stock options                                  |   |         | 33     |   |   |   | -      |                      |   |   | 172                 |   |   |                       | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 172 |   |
| Balance at June 30, 2012                                   |   |         | 34,077 |   |   | $      | 44     |                      |   | $      | 468,408             |   |   | $                          | (412,480 | )      |   | $      | (260 | ) |   |   | (200 | ) |   | $ | (2,741 | ) |   | $ | 52,971 |   |

----

|                                                                                                               |   | For the Six Months Ended |    |
|--------------------------------------------------------------------------------------------------------------------|--------|--------------------------|---------|
|                                                                                                               |   | June 30,                 |    |
|                                                                                                               |   | 2013                     |    |   | 2012 |   |
| Cash flows from operating activities:                                                                              |   |                          |    |   |  |   |
| Net loss                                                                                                           |   | $                        | (23,521 | ) |   | $ | (23,806 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities:                                        |   |                     |    |   |   |   |   |   |
| Depreciation and amortization                                                                                      |   |                     | 595     |   |   |   | 772 |   |
| Losses (gains) on sales of fixed assets                                                                            |   |                     | 259     |   |   |   | (217 | ) |
| Expenses for share-based compensation awards                                                                       |   |                     | 2,099   |   |   |   | 4,796 |   |
| Changes in assets and liabilities:                                                                                 |   |                     |    |   |   |   |   |   |
| Decrease (increase) in accounts receivable                                                                         |   |                     | 5,744   |   |   |   | (580 | ) |
| Decrease (increase) in other current assets                                                                        |   |                     | 812     |   |   |   | (106 | ) |
| (Decrease) in accounts payable and accrued expenses                                                                |   |                     | (2,508  | ) |   |   | (2,348 | ) |
| (Decrease) in deferred revenue - current                                                                           |   |                     | (780    | ) |   |   | - |   |
| (Decrease) in deferred revenue – long term                                                                   |   |                     | -       |   |   |   | (102 | ) |
| (Decrease) in other liabilities                                                                                    |   |                     | (163    | ) |   |   | (498 | ) |
| Net cash used in operating activities                                                                              |   |                     | (17,463 | ) |   |   | (22,089 | ) |
| Cash flows from investing activities:                                                                              |   |                     |    |   |   |   |   |   |
| Cash acquired in acquisition of subsidiary                                                                         |   |                     | 1,888   |   |   |   | - |   |
| Capital expenditures                                                                                               |   |                     | (47     | ) |   |   | (731 | ) |
| Proceeds from sales of fixed assets                                                                                |   |                     | 104     |   |   |   | 263 |   |
| Proceeds from redemption of auction rate securities                                                                |   |                     | 1,100   |   |   |   | 100 |   |
| Net cash provided by (used in) investing activities                                                                |   |                     | 3,045   |   |   |   | (368 | ) |
| Cash flows from financing activities:                                                                              |   |                     |    |   |   |   |   |   |
| Equity issuance costs in connection with acquisition of subsidiary                                                 |   |                     | (45     | ) |   |   | - |   |
| Proceeds from public offering of common stock, net of underwriting discounts and commissions and offering expenses |   |                     | 34,843  |   |   |   | - |   |
| Proceeds from the exercise of stock options                                                                        |   |                     | 3       |   |   |   | 172 |   |
| Net cash provided by financing activities                                                                          |   |                     | 34,801  |   |   |   | 172 |   |
| Net increase (decrease) in cash and cash equivalents                                                               |   |                     | 20,383  |   |   |   | (22,285 | ) |
| Cash and cash equivalents at beginning of period                                                                   |   |                     | 58,838  |   |   |   | 70,105 |   |
| Cash and cash equivalents at end of period                                                                         |   | $                        | 79,221  |   |   | $ | 47,820 |   |
|                                                                                                               |   |                     |    |   |   |   |   |   |
| Supplemental disclosure of cash flow information:                                                                  |   |                     |    |   |   |   |   |   |
| Acquisition-related contingent consideration liability                                                             |   | $                        | 15,900  |   |   | $ | - |   |
| Stock acquisition consideration                                                                                    |   | $                        | 11,265  |   |   | $ | - |   |

----

| 1. | Interim Financial Statements |
|----|------------------------------|

----

| 2. | Acquisition of Molecular Insight Pharmaceuticals, Inc. |
|----|--------------------------------------------------------|

----

|                                                                  |   | Amount |    |
|-----------------------------------------------------------------------|--------|--------|---------|
| Consideration:                                                        |   |        |    |
| Progenics common stock consideration                                  |   | $      | 11,265  |   |
| Contingent consideration (pursuant to future milestone obligations)   |   |   | 15,900  |   |
| Total consideration                                                   |   |   | 27,165  |   |
|                                                                  |   |   |    |   |
| Tangible assets acquired and liabilities assumed:                     |   |   |    |   |
| Cash and cash equivalents                                             |   |   | 1,888   |   |
| Accounts receivable                                                   |   |   | 56      |   |
| Other current assets                                                  |   |   | 529     |   |
| Fixed assets                                                          |   |   | 249     |   |
| Accounts payable, accrued expenses and deferred revenue - current     |   |   | (2,876  | ) |
| Deferred tax liability – long term                              |   |   | (12,683 | ) |
| Total tangible assets acquired and liabilities assumed                |   |   | (12,837 | ) |
|                                                                  |   |   |    |   |
| Intangible assets - in process research and development               |   |   | 32,300  |   |
| Total tangible and intangible assets acquired and liabilities assumed |   |   | 19,463  |   |
|                                                                  |   |   |    |   |
| Goodwill                                                              |   | $      | 7,702   |   |

|                             |   | Three Months EndedJune 30, |    |   | Six Months EndedJune 30, |   |
|----------------------------------|--------|----------------------------|---------|--------|--------------------------|--------|
|                             |   | 2013                       |    |   | 2012                     |   |   | 2013 |   |   | 2012 |   |
| Revenues                         |   | $                          | 1,801   |   |                     | $      | 1,836 |   |   | $ | 4,032 |   |   | $ | 4,148 |   |
| Net loss                         |   |                       | (12,223 | )      |                     |   | (17,740 | ) |   |   | (24,685 | ) |   |   | (38,011 | ) |
| Basic and diluted loss per share |   |                       | (0.24   | )      |                     |   | (0.46 | ) |   |   | (0.49 | ) |   |   | (0.99 | ) |

| 3. | Revenue Recognition |
|----|---------------------|

----

| 4. | Net Loss Per Share |
|----|--------------------|

|                             |   | Net Loss (Numerator) |    |   | Weighted Average Common Shares (Denominator)(in thousands) |   |   | Per Share Amount |   |
|----------------------------------|--------|----------------------|---------|--------|------------------------------------------------------------|--------|--------|------------------|--------|
| Three months ended June 30, 2013 |   |                      |    |   |                                                            |   |   |                  |   |
| Basic and diluted                |   | $                    | (12,263 | )      |                                                       |   | 51,481 |             |   | $ | (0.24 | ) |
| Six months ended June 30, 2013   |   |                 |    |   |                                                       |   |   |             |   |   |   |   |
| Basic and diluted                |   | $                    | (23,521 | )      |                                                       |   | 50,802 |             |   | $ | (0.46 | ) |
| Three months ended June 30, 2012 |   |                 |    |   |                                                       |   |   |             |   |   |   |   |
| Basic and diluted                |   | $                    | (10,720 | )      |                                                       |   | 33,798 |             |   | $ | (0.32 | ) |
| Six months ended June 30, 2012   |   |                 |    |   |                                                       |   |   |             |   |   |   |   |
| Basic and diluted                |   | $                    | (23,806 | )      |                                                       |   | 33,779 |             |   | $ | (0.70 | ) |

|                      |   | Three Months Ended June 30,          |
|---------------------------|--------|--------------------------------------|
|                      |   | 2013                                 |   |   | 2012 |
|                      |   | WeightedAverage Number(in thousands) |   |   | WeightedAverage Exercise Price |   |   | WeightedAverage Number(in thousands) |   |   | WeightedAverage Exercise Price |
| Options                   |   |                                 | 6,340 |   |   | $ | 11.62 |   |   |   | 6,227 |   |   | $ | 12.26 |
| Unvested restricted stock |   |                                 | - |   |   |   |   |   |   |   | 74 |   |   |   |   |
| Total                     |   |                                 | 6,340 |   |   |   |   |   |   |   | 6,301 |   |   |   |   |

----

|                      |   | Six Months Ended June 30,            |
|---------------------------|--------|--------------------------------------|
|                      |   | 2013                                 |   |   | 2012 |
|                      |   | WeightedAverage Number(in thousands) |   |   | WeightedAverage Exercise Price |   |   | WeightedAverage Number(in thousands) |   |   | WeightedAverage Exercise Price |
| Options                   |   |                                 | 6,036 |   |   | $ | 11.97 |   |   |   | 6,011 |   |   | $ | 12.35 |
| Unvested restricted stock |   |                                 | - |   |   |   |   |   |   |   | 85 |   |   |   |   |
| Total                     |   |                                 | 6,036 |   |   |   |   |   |   |   | 6,096 |   |   |   |   |

| 5. | Fair Value Measurements |
|----|-------------------------|

|                    |   |                         |   |   | Fair Value Measurements at June 30, 2013                      |
|-------------------------|--------|-------------------------|--------|--------|---------------------------------------------------------------|
| Investment Type         |   | Balance atJune 30, 2013 |   |   | Quoted Prices in Active Markets for Identical Assets(Level 1) |   |   | Significant Other Observable Inputs(Level 2) |   |   | Significant Unobservable Inputs(Level 3) |
|                    |   |                         |   |   |                                                               |   |   |  |   |   |  |
| Money market funds      |   | $                       | 70,345 |   |                                                          | $ | 70,345 |   |   | $ | - |   |   | $ | - |
| Auction rate securities |   |                    | 2,208  |   |                                                          |   | - |   |   |   | - |   |   |   | 2,208 |
| Total                   |   | $                       | 72,553 |   |                                                          | $ | 70,345 |   |   | $ | - |   |   | $ | 2,208 |

|                    |   |                             |   |   | Fair Value Measurements at December 31, 2012                  |
|-------------------------|--------|-----------------------------|--------|--------|---------------------------------------------------------------|
| Investment Type         |   | Balance atDecember 31, 2012 |   |   | Quoted Prices in Active Markets for Identical Assets(Level 1) |   |   | Significant Other Observable Inputs(Level 2) |   |   | Significant Unobservable Inputs(Level 3) |
|                    |   |                             |   |   |                                                               |   |   |  |   |   |  |
| Money market funds      |   | $                           | 56,224 |   |                                                          | $ | 56,224 |   |   | $ | - |   |   | $ | - |
| Auction rate securities |   |                        | 3,240  |   |                                                          |   | - |   |   |   | - |   |   |   | 3,240 |
| Total                   |   | $                           | 59,464 |   |                                                          | $ | 56,224 |   |   | $ | - |   |   | $ | 3,240 |

----

|                                                                                                                                                    |   | Fair Value Measurements Using SignificantUnobservable Inputs(Level 3)For the Three Months Ended June 30, |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------|--------|
| Description                                                                                                                                             |   | 2013                                                                                                     |   |   | 2012 |   |
|                                                                                                                                                    |   |                                                                                                          |   |   |  |   |
| Balance at beginning of period                                                                                                                          |   | $                                                                                                        | 3,148  |   |   | $ | 3,240 |   |
| Transfers into Level 3                                                                                                                                  |   |                                                                                                     | -      |   |   |   | - |   |
| Transfers out of Level 3                                                                                                                                |   |                                                                                                     | -      |   |   |   | - |   |
| Total gains (losses)                                                                                                                                    |   |                                                                                                     |   |   |   |   |   |   |
| Included in net loss                                                                                                                                    |   |                                                                                                     | -      |   |   |   | - |   |
| Included in other comprehensive loss                                                                                                                    |   |                                                                                                     | 60     |   |   |   | - |   |
| Settlements at par                                                                                                                                      |   |                                                                                                     | (1,000 | ) |   |   | - |   |
| Balance at end of period                                                                                                                                |   | $                                                                                                        | 2,208  |   |   | $ | 3,240 |   |
| Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets held at the end of the reporting period |   | $                                                                                                        | -      |   |   | $ | - |   |

|                                                                                                                                                    |   | Fair Value Measurements Using SignificantUnobservable Inputs(Level 3)For the Six Months Ended June 30, |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------|--------|
| Description                                                                                                                                             |   | 2013                                                                                                   |   |   | 2012 |   |
|                                                                                                                                                    |   |                                                                                                        |   |   |  |   |
| Balance at beginning of period                                                                                                                          |   | $                                                                                                      | 3,240  |   |   | $ | 3,332 |   |
| Transfers into Level 3                                                                                                                                  |   |                                                                                                   | -      |   |   |   | - |   |
| Transfers out of Level 3                                                                                                                                |   |                                                                                                   | -      |   |   |   | - |   |
| Total gains (losses)                                                                                                                                    |   |                                                                                                   |   |   |   |   |   |   |
| Included in net loss                                                                                                                                    |   |                                                                                                   | -      |   |   |   | - |   |
| Included in other comprehensive loss                                                                                                                    |   |                                                                                                   | 68     |   |   |   | 8 |   |
| Settlements at par                                                                                                                                      |   |                                                                                                   | (1,100 | ) |   |   | (100 | ) |
| Balance at end of period                                                                                                                                |   | $                                                                                                      | 2,208  |   |   | $ | 3,240 |   |
| Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets held at the end of the reporting period |   | $                                                                                                      | -      |   |   | $ | - |   |

----

| 6. | Accounts Receivable |
|----|---------------------|

|            | June 30, 2013 |   |   | December 31, 2012 |
|-----------------|---------------|--------|--------|-------------------|
| Collaborators   | $             | 60     |   |              | $ | 6,125 |
| Royalties       |          | 1,185  |   |              |   | 781 |
| Research grants |          | -      |   |              |   | 12 |
| Other           |          | 5      |   |              |   | 19 |
| Total           | $             | 1,250  |   |              | $ | 6,937 |

| 7. | Accounts Payable and Accrued Expenses |
|----|---------------------------------------|

|                                        | June 30, 2013 |   |   | December 31, 2012 |
|---------------------------------------------|---------------|--------|--------|-------------------|
| Accrued consulting and clinical trial costs | $             | 1,988  |   |              | $ | 2,193 |
| Accrued payroll and related costs           |          | 1,518  |   |              |   | 1,552 |
| Restructuring accrual                       |          | 537    |   |              |   | 813 |
| Legal and professional fees                 |          | 939    |   |              |   | 774 |
| Accounts payable                            |          | 859    |   |              |   | 229 |
| Other                                       |          | 120    |   |              |   | 79 |
| Total                                       | $             | 5,961  |   |              | $ | 5,640 |

----

|                         |   | Severance and Related Benefits |   |   | Other Exit Costs |   |   | Contract Termination Costs |   |   | Total Restructuring Accrual |   |
|------------------------------|--------|--------------------------------|--------|--------|------------------|--------|--------|----------------------------|--------|--------|-----------------------------|--------|
| Balance at December 31, 2012 |   | $                              | 813    |   |             | $      | -      |                       |   | $      | -                           |   |   | $ | 813 |   |
| Additions, net               |   |                           | 1,477  |   |             |   | -      |                       |   |   | -                           |   |   |   | 1,477 |   |
| Payments                     |   |                           | (854   | )      |             |   | -      |                       |   |   | -                           |   |   |   | (854 | ) |
| Balance at March 31, 2013    |   |                           | 1,436  |   |             |   | -      |                       |   |   | -                           |   |   |   | 1,436 |   |
| Additions, net               |   |                           | 15     |   |             |   | 15     |                       |   |   | 1,359                       |   |   |   | 1,389 |   |
| Payments                     |   |                           | (914   | )      |             |   | (15    | )                          |   |   | (1,359                      | )      |   |   | (2,288 | ) |
| Balance at June 30, 2013     |   | $                              | 537    |   |             | $      | -      |                       |   | $      | -                           |   |   | $ | 537 |   |

| 9. | Commitments and Contingencies |
|----|-------------------------------|

----

----

----

|           |   | Three Months EndedJune 30, |    |   |        |   |    | Six Months EndedJune 30, |   |   |        |   |
|----------------|--------|----------------------------|---------|--------|--------|--------|---------|--------------------------|--------|--------|--------|--------|
|           |   | 2013                       |    |   | 2012   |   |    | PercentChange       |   | 2013   |   |   | 2012 |   |   | PercentChange  |
|           |   |                            |    |   |        |   |    |                          |   |   |        |   |   |  |   |   |  |   |
| Revenues       |   | $                          | 1,801   |   |   | $      | 1,820   |                     |   |   | (1     | %)     |   | $ | 4,027 |   |   | $ | 4,046 |   |   |   | 0 | % |
| Expenses       |   |                       | (14,074 | )      |   |   | (12,554 | )                        |   |   | 12     | %      |   |   | (27,572 | ) |   |   | (27,881 | ) |   |   | (1 | %) |
| Operating loss |   |                       | (12,273 | )      |   |   | (10,734 | )                        |   |   | 14     | %      |   |   | (23,545 | ) |   |   | (23,835 | ) |   |   | (1 | %) |
| Other income   |   |                       | 10      |   |   |   | 14      |                     |   |   | (29    | %)     |   |   | 24 |   |   |   | 29 |   |   |   | (17 | %) |
| Net loss       |   | $                          | (12,263 | )      |   | $      | (10,720 | )                        |   |   | 14     | %      |   | $ | (23,521 | ) |   | $ | (23,806 | ) |   |   | (1 | %) |

|                  |   | Three Months EndedJune 30, |   |   |        |   |   | Six Months EndedJune 30, |   |   |        |   |
|-----------------------|--------|----------------------------|--------|--------|--------|--------|--------|--------------------------|--------|--------|--------|--------|
| Sources of Revenue    |   | 2013                       |   |   | 2012   |   |   | PercentChange       |   | 2013   |   |   | 2012 |   |   | PercentChange  |
|                  |   |                            |   |   |        |   |   |                          |   |   |        |   |   |  |   |   |  |   |
| Royalty income        |   | $                          | 1,176  |   |   | $      | 1,619  |                     |   |   | (27    | %)     |   | $ | 2,333 |   |   | $ | 3,453 |   |   |   | (32 | %) |
| Collaboration revenue |   |                       | 514    |   |   |   | 94     |                     |   |   | 447    | %      |   |   | 1,367 |   |   |   | 385 |   |   |   | 255 | % |
| Research grants       |   |                       | 77     |   |   |   | 88     |                     |   |   | (13    | %)     |   |   | 275 |   |   |   | 174 |   |   |   | 58 | % |
| Other revenues        |   |                       | 34     |   |   |   | 19     |                     |   |   | 79     | %      |   |   | 52 |   |   |   | 34 |   |   |   | 53 | % |
| Total                 |   | $                          | 1,801  |   |   | $      | 1,820  |                     |   |   | (1     | %)     |   | $ | 4,027 |   |   | $ | 4,046 |   |   |   | 0 | % |

|                           |   | Relistor Net Sales Reported by Collaborators |
|--------------------------------|--------|----------------------------------------------|
|                           |   | Three Months Ended June 30,                  |   |   | Six Months Ended June 30, |
|                           |   | 2013                                         |   |   | 2012 |   |   | 2013 |   |   | 2012 |
| U.S.                           |   | $                                            | 6,700 |   |   | $ | 10,000 |   |   | $ | 13,400 |   |   | $ | 21,300 |
| Ex-U.S.                        |   |                                         | 1,200 |   |   |   | 800 |   |   |   | 2,200 |   |   |   | 1,800 |
|     Global |   | $                                            | 7,900 |   |   | $ | 10,800 |   |   | $ | 15,600 |   |   | $ | 23,100 |

----

|                  |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|-----------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                  |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Salaries and benefits |   | $                           | 2,855  |   |   | $      | 3,532  |                      |   |   | (19    | %)     |   | $ | 7,496 |   |   | $ | 9,295 |   |   |   | (19 | %) |

|                     |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|--------------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                     |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Share-based compensation |   | $                           | 1,082  |   |   | $      | 1,290  |                      |   |   | (16    | %)     |   | $ | 1,581 |   |   | $ | 3,578 |   |   |   | (56 | %) |

|                 |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|----------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                 |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Clinical trial costs |   | $                           | 1,992  |   |   | $      | 489    |                      |   |   | 307    | %      |   | $ | 3,319 |   |   | $ | 1,079 |   |   |   | 208 | % |

----

|                                  |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|---------------------------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                                  |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Laboratory and manufacturing supplies |   | $                           | 421    |   |   | $      | 181    |                      |   |   | 133    | %      |   | $ | 460 |   |   | $ | 377 |   |   |   | 22 | % |

|                                      |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|-------------------------------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                                      |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Contract manufacturing and subcontractors |   | $                           | 572    |   |   | $      | 780    |                      |   |   | (27    | %)     |   | $ | 935 |   |   | $ | 1,624 |   |   |   | (42 | %) |

|        |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|-------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|        |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Consultants |   | $                           | 452    |   |   | $      | 113    |                      |   |   | 300    | %      |   | $ | 764 |   |   | $ | 223 |   |   |   | 243 | % |

|         |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|--------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|         |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| License fees |   | $                           | 153    |   |   | $      | 110    |                      |   |   | 39     | %      |   | $ | 223 |   |   | $ | 150 |   |   |   | 49 | % |

----

|            |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|-----------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|            |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Royalty expense |   | $                           | 119    |   |   | $      | 162    |                      |   |   | (27    | %)     |   | $ | 235 |   |   | $ | 347 |   |   |   | (32 | %) |

|                     |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|--------------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                     |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Other operating expenses |   | $                           | 2,694  |   |   | $      | 1,572  |                      |   |   | 71     | %      |   | $ | 4,234 |   |   | $ | 2,690 |   |   |   | 57 | % |

|                  |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|-----------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                  |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Salaries and benefits |   | $                           | 1,175  |   |   | $      | 1,656  |                      |   |   | (29    | %)     |   | $ | 2,569 |   |   | $ | 3,455 |   |   |   | (26 | %) |

|                     |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|--------------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                     |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Share-based compensation |   | $                           | 269    |   |   | $      | 897    |                      |   |   | (70    | %)     |   | $ | 519 |   |   | $ | 1,218 |   |   |   | (57 | %) |

|                             |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|----------------------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                             |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Consulting and professional fees |   | $                           | 896    |   |   | $      | 476    |                      |   |   | 88     | %      |   | $ | 2,400 |   |   | $ | 1,104 |   |   |   | 117 | % |

----

|                     |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|--------------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                     |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Other operating expenses |   | $                           | 1,076  |   |   | $      | 996    |                      |   |   | 8      | %      |   | $ | 2,242 |   |   | $ | 1,969 |   |   |   | 14 | % |

|                          |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|-------------------------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|                          |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Depreciation and amortization |   | $                           | 318    |   |   | $      | 300    |                      |   |   | 6      | %      |   | $ | 595 |   |   | $ | 772 |   |   |   | (23 | %) |

|            |   | Three Months Ended June 30, |   |   |        |   |   | Six Months Ended June 30, |   |   |        |   |
|-----------------|--------|-----------------------------|--------|--------|--------|--------|--------|---------------------------|--------|--------|--------|--------|
|            |   | 2013                        |   |   | 2012   |   |   | PercentChange        |   | 2013   |   |   | 2012 |   |   | PercentChange  |
| Interest income |   | $                           | 10     |   |   | $      | 14     |                      |   |   | (29    | %)     |   | $ | 24 |   |   | $ | 29 |   |   |   | (17 | %) |

----

----

|           |   | Six Months Ended June 30, |
|----------------|--------|---------------------------|
|           |   | 2013                      |   |   | 2012 |
| Oncology       |   | $                         | 18.2 |   |   | $ | 15.7 |
| Relistor       |   |                      | 0.4 |   |   |   | 1.2 |
| Other programs |   |                      | 0.6 |   |   |   | 2.5 |
| Total          |   | $                         | 19.2 |   |   | $ | 19.4 |

|                                  |   |               |   |   | Payments due by June 30, |
|---------------------------------------|--------|---------------|--------|--------|--------------------------|
|                                  |   | Total         |   |   | 2014                     |   |   |   | 2015-2016 |   |   |   | 2017-2018 |   |   | Thereafter |
|                                  |   | (in millions) |
| Operating leases                      |   | $             | 14.8   |   |                     | $ | 1.8 |   |   | $ | 3.8 |   |   | $ | 4.0 |   |   | $ | 5.2 |
| License and collaboration agreements: |   |          |   |   |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Fixed payments                        |   |          | 1.4    |   |                     |   | 0.5 |   |   |   | 0.4 |   |   |   | 0.4 |   |   |   | 0.1 |
| Contingent payments (1)               |   |          | 90.0   |   |                     |   | 0.1 |   |   |   | 2.4 |   |   |   | 5.4 |   |   |   | 82.1 |
| Total                                 |   | $             | 106.2  |   |                     | $ | 2.4 |   |   | $ | 6.6 |   |   | $ | 9.8 |   |   | $ | 87.4 |

|                                (1) | Based on assumed achievement of milestones covered under each agreement, the timing and payment of which is highly uncertain. |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

| · | It might not obtain labeling claims necessary to make the product commercially viable (in general, labeling claims define the medical conditions for which a drug product may be marketed, and are therefore very important to the commercial success of a product), or may be required to carry Boxed or other warnings that adversely affect its commercial success. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Approval may be limited to uses of the product for treatment or prevention of diseases or conditions that are relatively less financially advantageous to us than approval of greater or different scope or subject to an FDA-imposed REMS that imposes limits on the distribution or use of the product. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Side effects identified after the product is on the market might hurt sales or result in mandatory safety labeling changes, additional pre-clinical testing or clinical trials, imposition of a REMS, product recalls or withdrawals from the market. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Efficacy or safety concerns regarding a marketed product, or manufacturing or other problems, may lead to a recall, withdrawal of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling, imposition of a REMS, the need for additional marketing applications, declining sales or other adverse events. These potential consequences may occur whether or not the concerns originate from subsequent testing or other activities by us, governmental regulators, other entities or organizations or otherwise, and whether or not they are scientifically justified. If products lose previously received marketing and other approvals, our business, results of operations and financial condition would be materially adversely affected. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

----

----

----

----

----

----

----

----

----

| Item 6. | Exhibits |
|---------|----------|

| Exhibit Number | Description                                                                                                                                                                                                                                         |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           |                                                                                                                                                                                                                                                |
| 12.1           | Statement re computation of ratio of earnings (loss) to combined fixed charges and preferred stock dividends.                                                                                                                                       |
|           |                                                                                                                                                                                                                                                |
| 31.1           | Certification of Mark R. Baker, Chief Executive Officer of the Registrant, pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.                                                                     |
|           |                                                                                                                                                                                                                                                |
| 31.2           | Certification of Angelo W. Lovallo, Jr., Vice President, Finance and Treasurer (Principal Financial and Accounting Officer) of the Registrant, pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended. |
|           |                                                                                                                                                                                                                                                |
| 32             | Certification of the Chief Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                               |
|           |                                                                                                                                                                                                                                                |
| 101            | Interactive Data File                                                                                                                                                                                                                               |
|           |                                                                                                                                                                                                                                                |
| 101.INS        | XBRL Instance Document                                                                                                                                                                                                                              |
|           |                                                                                                                                                                                                                                                |
| 101.SCH        | XBRL Taxonomy Extension Schema                                                                                                                                                                                                                      |
|           |                                                                                                                                                                                                                                                |
| 101.CAL        | XBRL Taxonomy Extension Calculation Linkbase                                                                                                                                                                                                        |
|           |                                                                                                                                                                                                                                                |
| 101.LAB        | XBRL Taxonomy Extension Label Linkbase                                                                                                                                                                                                              |
|           |                                                                                                                                                                                                                                                |
| 101.PRE        | XBRL Taxonomy Extension Presentation Linkbase                                                                                                                                                                                                       |
|           |                                                                                                                                                                                                                                                |
| 101.DEF        | XBRL Taxonomy Extension Definition Document                                                                                                                                                                                                         |
|           |                                                                                                                                                                                                                                                |

----

|                 | PROGENICS PHARMACEUTICALS, INC. |
|----------------------|---------------------------------|
| Date: August 9, 2013 | By:                             | /s/ Angelo W. Lovallo, Jr. |
|                 |                            | Angelo W. Lovallo, Jr.Vice President, Finance & Treasurer(Principal Financial and Accounting Officer) |